SCHEMBL21566460

SCHEMBL21566460

O=C(OC1OC2COC(=O)c3cc(O)c(O)c(O)c3-c3c(cc(O)c(O)c3O)C(=O)OC2C(O)C1OC(=O)c1cc(O)c(O)c(O)c1)c1cc(O)c(O)c(O)c1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.85
RAD52 P43351 2/20 0.85
F10 P00742 1/20 0.85
PRKD3 O94806 9/20 0.82
PRKCG P05129 9/20 0.82
PRKCB P05771 9/20 0.82
PRKCA P17252 9/20 0.82
PRKCH P24723 9/20 0.82
PRKCI P41743 9/20 0.82
PRKCE Q02156 9/20 0.82
PRKCQ Q04759 9/20 0.82
PRKCZ Q05513 9/20 0.82
PRKCD Q05655 9/20 0.82
PRKD1 Q15139 9/20 0.82
USP2 O75604 1/20 0.79
LMNA P02545 1/20 0.79
POLB P06746 1/20 0.79
GAA P10253 1/20 0.79
MAPT P10636 1/20 0.79
HPGD P15428 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12824705 0.92 BACE1 (0.85) BACE1RAD52F10PRKD3PRKCG
SCHEMBL30385544 0.92 BACE1 (0.85) BACE1RAD52F10PRKD3PRKCG
Strictinin SCHEMBL15262426 0.92 RAD52 (1.00) BACE1RAD52F10PRKD3PRKCG
Strictinin SCHEMBL15281508 0.92 RAD52 (1.00) BACE1RAD52F10PRKD3PRKCG
Tellimagrandin Ii SCHEMBL29369707 0.92 BACE1 (1.00) BACE1RAD52F10PRKD3PRKCG
Eugeniin SCHEMBL618554 0.92 BACE1 (1.00) BACE1RAD52F10PRKD3PRKCG
Strictinin SCHEMBL14614086 0.92 RAD52 (1.00) BACE1RAD52F10PRKD3PRKCG
Eugeniin SCHEMBL618555 0.92 BACE1 (1.00) BACE1RAD52F10PRKD3PRKCG
Strictinin SCHEMBL17148972 0.92 RAD52 (1.00) BACE1RAD52F10PRKD3PRKCG
Strictinin SCHEMBL29369362 0.92 RAD52 (1.00) BACE1RAD52F10PRKD3PRKCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230190854-A1 METHOD OF REDUCING MUSCLE DAMAGE ASSOCIATED WITH INTENSIVE EXERCISE BY ADMINISTERING PURPLE-TEA EXTRACT ORYZA OIL & FAT CHEMICAL CO., LTD. (JP) 2023-06-22 US disclosed
US-20230190854-A1 METHOD OF REDUCING MUSCLE DAMAGE ASSOCIATED WITH INTENSIVE EXERCISE BY ADMINISTERING PURPLE-TEA EXTRACT ORYZA OIL & FAT CHEMICAL CO., LTD. (JP) 2023-06-22 US disclosed
US-20190343858-A1 METHOD OF REGULATING THE CIRCADIAN RHYTHM OF AN INDIVIDUAL COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF A CIRCADIAN RHYTHM REGULATOR CONTAINING 1,2-DI-O-GALLOYL-4,6-O-(S)-HEXAHYDROXYDIPHENOYL-B-D-GLUCOSE ORYZA OIL & FAT CHEMICAL CO., LTD. (JP) 2019-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230190854-A1 METHOD OF REDUCING MUSCLE DAMAGE ASSOCIATED WITH INTENSIVE EXERCISE BY ADMINISTERING PURPLE-TEA EXTRACT PYGM, MUSK, GCK BACE1 4702/4885RAD52 1296/4885F10 3540/4885
US-20190343858-A1 METHOD OF REGULATING THE CIRCADIAN RHYTHM OF AN INDIVIDUAL COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF A CIRCADIAN RHYTHM REGULATOR CONTAINING 1,2-DI-O-GALLOYL-4,6-O-(S)-HEXAHYDROXYDIPHENOYL-B-D-GLUCOSE PER2, CRY1, GCKR BACE1 1869/4885RAD52 1441/4885F10 3087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.